Open Access

Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA‑treated HepG2 cells

  • Authors:
    • Yayun Liu
    • Lu Liao
    • Yong Chen
    • Fengmei Han
  • View Affiliations

  • Published online on: April 5, 2019     https://doi.org/10.3892/mmr.2019.10139
  • Pages: 4673-4684
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Non‑alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, and has high rates of morbidity and mortality worldwide. Daphnetin (DAP) possesses notable antioxidative, anti‑inflammatory and anticoagulant activities; DAP is an active ingredient extracted from Daphne Koreana Nakai. To investigate the effects and the underlying mechanism of DAP on NAFLD, we treated HepG2 cells with oleic acid (OA) and DAP simultaneously and non‑simultaneously. In the simultaneous treatment condition, HepG2 cells were co‑treated with 0.5 mM OA and DAP (5, 20, and 50 µM) for 24 h. In the non‑simultaneous treatment conditions, HepG2 cells were pretreated with 0.5 mM OA for 24 h, and then treated with DAP (5, 20 and 50 µM) for 24 h. Following the aforementioned treatments, the biochemical indexes associated with NAFLD were measured as follows: i) The intracellular contents of triglyceride (TG), reactive oxygen species (ROS) and fluorescent glucose 2‑[N‑(7‑nitrobenz‑2‑oxa‑1,3‑diazol‑4‑yl) amino]‑2‑deoxyglucose were analyzed with corresponding detection kits; and ii) the cellular expression levels of glycolipid metabolism‑ and oxidative stress‑related genes, including 5'AMP‑activated protein kinase (AMPK), sterol regulatory element‑binding protein‑1C (SREBP‑1C), patatin‑like phospholipase domain‑containing protein 3 (PNPLA3), peroxisome proliferator‑activated receptor α (PPARα), phosphoinositide 3‑kinase (PI3K), protein kinase B (AKT), nuclear factor‑like 2 (Nrf2), cytochrome P450 (CYP) 2E1 and CYP4A were determined by reverse transcription‑quantitative polymerase chain reaction and western blotting. The results revealed the potential mechanism underlying the effects of DAP on NAFLD in vitro: i) By increasing the phosphorylation of AMPK, DAP inhibited the expression of SREBP‑1C and PNPLA3, and induced that of PPARα. Lipid accumulation within hepatocytes was reduced; ii) by upregulating PI3K expression and pAKT/AKT levels, DAP may alleviate insulin resistance and promote hepatocellular glucose uptake; and iii) by upregulating the expression of Nrf2, DAP downregulated the expression of CYP2E1 and CYP4A, and the levels of reactive oxygen species in hepatocytes.

References

1 

Issa D, Patel V and Sanyal AJ: Future therapy for non-alcoholic fatty liver disease. Liver Int. 38 (Suppl 1):S56–S63. 2018. View Article : Google Scholar

2 

Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T and Lindor K: Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 41:64–71. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Tilg H and Moschen AR: Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 52:1836–1846. 2010. View Article : Google Scholar : PubMed/NCBI

4 

Anstee QM and Goldin RD: Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 87:1–16. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Review Team, LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, Hamid SS, Isakov V, Lizarzabal M, et al: World gastroenterology organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 48:467–473. 2014.PubMed/NCBI

6 

Lee YH, Kim KJ, Yoo ME, Kim G, Yoon HJ, Jo K, Youn JC, Yun M, Park JY, Shim CY, et al: Association of nonalcoholicsteatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J Hepatol. 68:764–772. 2018. View Article : Google Scholar : PubMed/NCBI

7 

Marra F, Gastaldelli A, Svegliati Baroni G, Tell G and Tiribelli C: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 14:72–81. 2008. View Article : Google Scholar : PubMed/NCBI

8 

Sumida Y and Yoneda M: Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 53:362–376. 2018. View Article : Google Scholar : PubMed/NCBI

9 

Takahashi Y, Suqimoto K, Inui H and Fukusato T: Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 21:3777–3785. 2015. View Article : Google Scholar : PubMed/NCBI

10 

Liu J, Tian J, He W, Xie J, Hu Z and Chen X: Spectrofluorimetric study of the binding of daphnetin to bovine serum albumin. J Pharm Biomed Anal. 35:671–677. 2004. View Article : Google Scholar : PubMed/NCBI

11 

Finn GJ, Creaven BS and Egan DA: Daphnetin induced differentiation of human renal carcinoma cells and its mediation by p38 mitogen-activated protein kinase. Biochem Pharmacol. 67:1779–1788. 2004. View Article : Google Scholar : PubMed/NCBI

12 

Lv H, Liu Q, Zhou J, Tan G, Deng X and Ci X: Daphnetin-mediated Nrf2 antioxidant signaling pathways ameliorate tert-butyl hydroperoxide (t-BHP)-induced mitochondrial dysfunction and cell death. Free Radic Biol Med. 106:38–52. 2017. View Article : Google Scholar : PubMed/NCBI

13 

Venugopala KN, Rashmi V and Odhav B: Review on natural coumarin lead compounds for their pharmacological activity. Biomed Res Int. 2013:9632482013. View Article : Google Scholar : PubMed/NCBI

14 

Um MY, Moon MK, Ahn J and Youl Ha T: Coumarin attenuates hepatic steatosis by down-regulating lipogenic gene expression in mice fed a high-fat diet. Br J Nut. 109:1590–1597. 2013. View Article : Google Scholar

15 

Yu W, Wang H, Ying H, Yu Y, Chen D, Ge W and Shi L: Daphnetin attenuates microglial activation and proinflammatory factor production via multiple signaling pathways. Int Immunopharmacol. 21:1–9. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

17 

Harrison SA, Oliver D, Arnold HL, Gogia S and Neuschwander-Tetri BA: Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 57:1441–1447. 2008. View Article : Google Scholar : PubMed/NCBI

18 

Vacca M, Allison M, Griffin JL and Vidal-Puig A: Fatty acid and glucose sensors in hepatic lipid metabolism: Implications in NAFLD. Semin Liver Dis. 35:250–261. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH and Dobbins RL: Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 288:E462–E468. 2005. View Article : Google Scholar : PubMed/NCBI

20 

Kanuri G and Bergheim I: In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci. 14:11963–11980. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Rafiei H, Omidian K and Bandy B: Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosis. Mol Nutr Food Res. 61:2017. View Article : Google Scholar : PubMed/NCBI

22 

Xie C, Chen Z, Zhang C, Xu X, Jin J, Zhan W, Han T and Wang J: Dihydromyricetin ameliorates oleic acid-induced lipid accumulation in L02 and HepG2 cells by inhibiting lipogenesis and oxidative stress. Life Sci. 157:131–139. 2016. View Article : Google Scholar : PubMed/NCBI

23 

Fan JG, Wei L and Zhuang H: National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Disease Expert Committee, Chinese Medical Doctor Association: Guideline of prevention and treatment of nonalcoholic fatty liver disease (2018, China). J Dig Dis. Nov 16–2018.(Epub ahead of print).

24 

Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ and Steinberg GR: Treatment of nonalcoholic fatty liver disease: Role of AMPK. Am J Physiol Endocrinol Metab. 311:E730–E740. 2016. View Article : Google Scholar : PubMed/NCBI

25 

Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Enjoji M, et al: SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med. 21:507–511. 2008.PubMed/NCBI

26 

Ruderman NB, Carling D, Prentki M and Cacicedo JM: AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest. 123:2764–2772. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Ahmed MH and Byrne CD: Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today. 12:740–747. 2007. View Article : Google Scholar : PubMed/NCBI

28 

Dubuquoy C, Robichon C, Lasnier F, Langlois C, Dugail I, Foufelle F, Girard J, Burnol AF, Postic C and Moldes M: Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. J Hepatolv. 55:145–153. 2011. View Article : Google Scholar

29 

Seo YS, Ji HK, Jo NY, Choi KM, Baik SH, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, et al: PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol. 23:102–109. 2008.PubMed/NCBI

30 

Zheng T, Yang X, Wu D, Xing S, Bian F, Li W, Chi J, Bai X, Wu G, Chen X, et al: Salidroside ameliorates insulin resistance through activation of a mitochondria-associated AMPK/PI3K/Akt/GSK3β pathway. Br J Pharmacol. 172:3284–3301. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Sanyal AJ, Campbellsargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML and Clore JN: Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 120:1183–1192. 2001. View Article : Google Scholar : PubMed/NCBI

32 

Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E and Defronzo RA: Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 133:496–506. 2007. View Article : Google Scholar : PubMed/NCBI

33 

Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E and Rizzetto M: Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms. Diabetologia. 48:634–642. 2005. View Article : Google Scholar : PubMed/NCBI

34 

Dunaif A: Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev. 18:774–800. 1997. View Article : Google Scholar : PubMed/NCBI

35 

Hotamisligil GS, Shargill NS and Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science. 259:87–91. 1993. View Article : Google Scholar : PubMed/NCBI

36 

Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 7:941–946. 2001. View Article : Google Scholar : PubMed/NCBI

37 

Shoelson SE, Lee J and Goldfine AB: Inflammation and insulin resistance. J Clin Invest. 116:1793–1807. 2006. View Article : Google Scholar : PubMed/NCBI

38 

Sharma BR, Kim HJ and Rhyu DY: Caulerpa lentillifera extract ameliorates insulin resistance and regulates glucose metabolism in C57BL/KsJ-db/db mice via PI3K/AKT signaling pathway in myocytes. J Transl Med. 13:622015. View Article : Google Scholar : PubMed/NCBI

39 

Sanyal AJ, Campbellsargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML and Clore JN: Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 120:1183–1192. 2001. View Article : Google Scholar : PubMed/NCBI

40 

Rao MS and Reddy JK: Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis. 21:43–55. 2001. View Article : Google Scholar : PubMed/NCBI

41 

Schattenberg JM and Czaja MJ: Regulation of the effects of CYP2E1-induced oxidative stress by JNK signaling. Redox Biol. 3:7–15. 2014. View Article : Google Scholar : PubMed/NCBI

42 

Shen L, Zhou T, Wang J, Sang X, Lan L, Luo L and Yin Z: Daphnetin reduces endotoxin lethality in mice and decreases LPS-induced inflammation in Raw264.7 cells via suppressing JAK/STATs activation and ROS production. Inflamm Res. 66:579–589. 2017. View Article : Google Scholar : PubMed/NCBI

43 

Li M, Shi X, Chen F and Hao F: Daphnetin inhibits inflammation in the NZB/W F1 systemic lupus erythematosus murine model via inhibition of NF-κB activity. Exp Ther Med. 13:455–460. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 19 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, Y., Liao, L., Chen, Y., & Han, F. (2019). Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA‑treated HepG2 cells. Molecular Medicine Reports, 19, 4673-4684. https://doi.org/10.3892/mmr.2019.10139
MLA
Liu, Y., Liao, L., Chen, Y., Han, F."Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA‑treated HepG2 cells". Molecular Medicine Reports 19.6 (2019): 4673-4684.
Chicago
Liu, Y., Liao, L., Chen, Y., Han, F."Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA‑treated HepG2 cells". Molecular Medicine Reports 19, no. 6 (2019): 4673-4684. https://doi.org/10.3892/mmr.2019.10139